Quinazoline antifolate thymidylate synthase inhibitors: alkyl, substituted alkyl, and aryl substituents in the C-2 position
- 1 November 1990
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 33 (11) , 3060-3067
- https://doi.org/10.1021/jm00173a024
Abstract
Modification of the potent thymidylate synthase (TS) inhibitor N-[4-[N-[2-amino-3,4-dihydro-4-oxo-6-quinazolinyl)methyl]-N-prop-2-ynylamino]benzoyl]-L-glutamic acid (1a) has led to the synthesis of quinazoline antifolates bearing alkyl, substituted alkyl, and aryl substituents at C2. In general the synthetic route involved the coupling of the appropriate diethyl N-[4-(alkylamino)benzoyl]-L-glutamate with a C2-substituted 6-(bromomethyl)-3,4-dihydro-4-oxoquinazoline followed by deprotection using mild alkali. Good enzyme inhibition and cytotoxicity were found with compounds containing small nonpolar groups in the C2 position with the 2-desamino-2-methyl analogue 3a being the most potent. Larger C2 substituents were tolerated by the enzyme, but cytotoxicity was reduced. Highly potent series were followed up by the synthesis of a number of analogues in which the n10 substituent was varied. In this manner a number of interesting TS inhibitors have been prepared. Although none of these was more potent than 1a against the isolated enzyme, over half of the compounds prepared were more potent as cytotoxic agents against L1210 cells in culture. The potential of such compounds as useful antitumor agents was further enhanced by the finding that the improved aqueous solubilities of compounds such as 3a over 1a were reflected in vivo in that 3a was at least 5 times less toxic to mice than 1a.This publication has 12 references indexed in Scilit:
- Quinazoline antifolates inhibiting thymidylate synthase: synthesis of four oligo(L-.gamma.-glutamyl) conjugates of N10-propargyl-5,8-dideazafolic acid and their enzyme inhibitionJournal of Medicinal Chemistry, 1989
- Formation and retention and biological activity of N10-propargyl-5, 8-dideazafolic acid (CB3717) polyglutamates in L1210 cells in vitroBiochemical Pharmacology, 1988
- Induction of remission in hepatocellular carcinoma with a new thymidylate synthase inhibitor, CB3717Journal of Hepatology, 1987
- PHARMACOKINETICS OF THE THYMIDYLATE SYNTHASE INHIBITOR N-10-PROPARGYL-5,8-DIDEAZAFOLIC ACID (CB3717) IN THE MOUSE1986
- A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717.Journal of Clinical Oncology, 1986
- INCREASED THYMIDYLATE SYNTHASE IN L1210 CELLS POSSESSING ACQUIRED-RESISTANCE TO N-10-PROPARGYL-5,8-DIDEAZAFOLIC ACID (CB3717) - DEVELOPMENT, CHARACTERIZATION, AND CROSS-RESISTANCE STUDIES1986
- Quinazoline antifolates inhibiting thymidylate synthase: variation of the N10 substituentJournal of Medicinal Chemistry, 1985
- A potent antitumour quinazoline inhibitor of thymidylate synthetase: Synthesis, biological properties and therapeutic results in micePublished by Elsevier ,1981
- A Novel Synthesis of 2-Substituted Quinazolin-4(3H)-onesHETEROCYCLES, 1981
- Analogs of methotrexateJournal of Medicinal Chemistry, 1979